PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-5.12%
Both companies show declining cash positions (-5.12% vs RVPH's -11.36%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-5.12%
Below half of RVPH's -11.36%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
820.83%
Above 1.5x RVPH's 326.54%. Michael Burry might investigate for potential short-term asset misclassification or risk.
-4.22%
0.5-0.75x RVPH's -7.35%. Martin Whitman might see risk if this hampers near-term financial flexibility.
-17.65%
Both RVPH and the company show zero PP&E (Net) Growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Both RVPH and the company show zero Long-Term Investments Growth.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Higher Other Non-Current Assets Growth compared to RVPH's zero value, indicating worse performance.
-47.54%
Both RVPH and the company show zero Total Non-Current Assets Growth.
No Data
No Data available this quarter, please select a different quarter.
-4.84%
0.5-0.75x RVPH's -7.35%. Martin Whitman worries about slower asset growth than competitor. Is it strategy or constraint?
46.70%
Above 1.5x RVPH's 21.10%. Michael Burry questions if payables are being stretched to avoid short-term borrowing.
-26.38%
Higher Short-Term Debt Growth compared to RVPH's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
126.45%
Higher Deferred Revenue (Current) Growth compared to RVPH's zero value, indicating better performance.
265.71%
1.1-1.25x RVPH's 231.92%. Bill Ackman wonders if the firm is incurring more one-time charges than competitor.
63.25%
Less than half of RVPH's 140.81%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-25.00%
50-75% of RVPH's -42.73%. Bruce Berkowitz notes a smaller yoy liability buildup than competitor.
No Data
No Data available this quarter, please select a different quarter.
63.16%
Similar yoy to RVPH's 67.28%. Walter Schloss sees parallel expansions in total liabilities.
No Data
No Data available this quarter, please select a different quarter.
-3.23%
0.5-0.75x RVPH's -5.84%. Martin Whitman is wary of weaker retention or lower profitability.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-8.40%
0.75-0.9x RVPH's -11.10%. Bill Ackman wonders if competitor is growing equity faster.
-4.84%
0.5-0.75x RVPH's -7.35%. Martin Whitman sees underexpansion or possible missed opportunities.
-100.00%
Both RVPH and the company show zero Total Investments Growth.
-26.37%
Higher Total Debt Growth compared to RVPH's zero value, indicating worse performance.
5.01%
Less than half of RVPH's 11.36%. David Dodd sees better deleveraging or stronger cash buildup than competitor.